Alnylam may be gearing up for its biggest commercial launch yet in its nearly 23-year history, but the company’s top ...

RA Capital leads as most active venture player in private biotech rounds through 2024, with ARCH participating in fewer but ...

Eli Lilly will start selling additional single-dose vials of its weight loss drug Zepbound at a lower price for certain ...

Me CEO Anne Wojcicki and New Mountain Capital propose $2.53/share buyout to take company private, valuing it at $74.7M after ...

With help from its $43 billion Seagen merger, Pfizer will contribute its antibody-drug conjugates to Summit Therapeutics' ...

Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...

Amgen to invest $200M in new Hyderabad tech center through 2025, focusing on AI for drug development. Site opened Monday with ...

Phase 1b US study planned for 2026, as company competes with NS Pharma and Avidity Biosciences in exon 44 space ...

So far, only 22% of life sciences organizations have adopted AI at scale, yet 86% of healthcare and life sciences leaders ...

FDA denies Invivyd's EUA expansion for Pemgarda in Covid treatment while BioCryst reports positive Orladeyo data. AN2 changes endpoint, OS Therapies seeks partners & Eyenovia restructures.

UnitedHealthcare offers voluntary buyouts to 30,000 employees due to low attrition and digital shift, COO Michael Baker tells ...

As he was testing new antivirals to halt a future pandemic, John Chodera encountered an unlikely set of new problems that ...